Dr. Ferris Discusses the RTOG 3504 Study in Head and Neck Cancer
Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute discusses the RTOG 3504 study in head and neck cancer.
Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute discusses the RTOG 3504 study in head and neck cancer.
This was a randomized phase II study of chemoradiation with or without nivolumab (Opdivo) with sequential safety evaluations of nivolumab with or without lirilumab or ipilimumab (Yervoy) concomitant with chemoradiation in intermediate- and high-risk head and neck squamous cell carcinoma.
Ferris says that the trial aims to look at an intensification of the standard-of-care by adding immunotherapy.
